These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 12915677)

  • 1. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm.
    Lonergan M; Aponso D; Marvin KW; Helliwell RJ; Sato TA; Mitchell MD; Chaiwaropongsa T; Romero R; Keelan JA
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3835-44. PubMed ID: 12915677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.
    Pritzker LB; Scatena M; Giachelli CM
    Mol Biol Cell; 2004 Jun; 15(6):2834-41. PubMed ID: 15064358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
    Zhang XD; Franco AV; Nguyen T; Gray CP; Hersey P
    J Immunol; 2000 Apr; 164(8):3961-70. PubMed ID: 10754286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells.
    Hueber A; Aduckathil S; Kociok N; Welsandt G; Dinslage S; Kirchhof B; Esser PJ
    Graefes Arch Clin Exp Ophthalmol; 2002 Jul; 240(7):551-6. PubMed ID: 12136286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
    Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
    J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.
    Zhang XD; Franco A; Myers K; Gray C; Nguyen T; Hersey P
    Cancer Res; 1999 Jun; 59(11):2747-53. PubMed ID: 10364001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
    Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
    Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
    Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
    Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and functional activity of osteoprotegerin in human malignant gliomas.
    Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
    Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
    Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
    Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of tumor necrosis factor- alpha -related apoptosis-inducing ligand and its proapoptotic receptors is down-regulated during gastric infection with virulent cagA+/vacAs1+ Helicobacter pylori strains.
    Neu B; Rad R; Reindl W; Neuhofer M; Gerhard M; Schepp W; Prinz C
    J Infect Dis; 2005 Feb; 191(4):571-8. PubMed ID: 15655781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
    J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of the death ligand TRAIL and its receptors.
    Spierings DC; de Vries EG; Vellenga E; van den Heuvel FA; Koornstra JJ; Wesseling J; Hollema H; de Jong S
    J Histochem Cytochem; 2004 Jun; 52(6):821-31. PubMed ID: 15150291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
    Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
    Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial cell-derived neutrophil-activating peptide-78 is present in fetal membranes and amniotic fluid at increased concentrations with intra-amniotic infection and preterm delivery.
    Keelan JA; Yang J; Romero RJ; Chaiworapongsa T; Marvin KW; Sato TA; Mitchell MD
    Biol Reprod; 2004 Jan; 70(1):253-9. PubMed ID: 13679321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
    Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
    Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
    Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.